Weekly View

ICER Weekly View: January 18, 2019

From the desk of David Whitrap Good morning everyone. Here in Boston, we’ve seen exactly 0.2 inches of snowfall this winter. For those keeping score at home, that’s 22.7 inches less than what we’d seen by this time last year, and it’s half of what’s already fallen this season in famously frigid cities like El […]

Read More

ICER Weekly View: January 11, 2019

From the desk of David Whitrap Good morning, everyone. This week’s JP Morgan Healthcare Conference brought us some big M&A deals, promising clinical trial data, and a slight (okay, very slight) improvement toward gender balance among the executives who presented. Let’s take a brief look at the news… Pharmaceutical News On the heels of Bristol-Myers […]

Read More

ICER Weekly View: January 4, 2019

From the desk of David Whitrap Good morning and Happy New Year! Each January brings optimism, fresh starts, and resolutions to be our best selves. It also sets up the annual battle: will our high-minded intentions be able to conquer well-entrenched habits? A new Congress was sworn in this week, but as of this moment, […]

Read More

ICER Weekly View 12-14-18

From the desk of Mitchell Stein   Good morning. It is with mixed feelings that I write that this will be my final issue of Weekly View. In 2011 I became a member of New England CEPAC, then in May of 2015 I joined the staff of ICER and started sharing a few articles each […]

Read More

ICER Weekly View 12-07-18

From the desk of Mitchell Stein   Good morning. My crystal ball is cloudy! On the one hand, news this week that Grassley and Wyden (the incoming chairman and ranking member of the Senate Finance Committee) introduced a drug pricing bill together makes one think there is a chance of movement on the issue in […]

Read More

ICER Weekly View 11-30-18

From the desk of Mitchell Stein   Good morning. Only Nixon could go to China, and only Kirk could make peace with the Klingons. Does that mean only a Republican can reform Medicare drug pricing? If the current Administration’s proposals move forward, that will be the relevant correlation (although it goes without saying that we […]

Read More

ICER Weekly View 11-16-18

From the desk of Mitchell Stein   Good morning. Happy almost gobble gobble – wishing you all Happy Thanksgiving now as we’ll be taking next week off to cook and stuff ourselves (stuff yourself indiscriminately, but if you stuff your turkey, safety first, make sure the stuffing gets to 165). But before we go, we […]

Read More

ICER Weekly View 11-09-18

From the desk of Mitchell Stein   Good morning. Did you hear there was an election this week? Well, there was, and the changes it brings may have an impact on pharma. We’ll take a look a look at several pieces discussing the ramifications as well as the rest of the week’s news. Here’s the […]

Read More

ICER Weekly View 11-02-18

From the desk of Mitchell Stein   Good morning. Before we get started, I’d like to talk about civic engagement. In as non-partisan a way as possible, I encourage you to engage in the following three ways: First, get your flu shot. If you’re reading this newsletter, I have to believe that you know they […]

Read More

ICER Weekly View 10-26-18

From the desk of Mitchell Stein   Good morning. Presidential speeches, Wall Street Journal profiles, price changes, drug approvals, PBM developments… So much news, so little time so let’s get right to it. This week we’ll look at: ICER in the News – WSJ profile of John Arnold, evidence report on extended-release opioid use disorder treatments, […]

Read More

Sign-up to have the Weekly View delivered to your inbox every Friday morning.

SIGN UP